Statements Data availability statement The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding authors
The net result of AOD9604 action is preferential reduction of adipose tissue mass, particularly visceral and subcutaneous fat depots, without the hyperglycemic, insulin-desensitizing, or growth-promoting effects of full-length growth hormone
AOD9604 is a modified fragment of human growth hormone (HGH), specifically designed to target fat metabolism without influencing growth hormone levels or GHRP-2 Dosage Guide: Benefits, Usage & Research Applications April 18, 2026 Introduction GHRP-2 dosage for growth hormone release is a widely discussed topic in peptide and endocrine research
For researchers and interested readers, monitoring registered clinical trial databases such as ClinicalTrials.gov and peer-reviewed preclinical journals remains the most reliable way to track meaningful new developments